Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06337864
Other study ID # H-24017055
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 2024
Est. completion date December 2027

Study information

Verified date March 2024
Source Rigshospitalet, Denmark
Contact Allan Lund, Professor, MD, DMSc
Phone +45 3545 1303
Email allan.lund@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research investigates the effectiveness and safety of large neutral amino acid (LNAA) supplementation in patients with classical phenylketonuria (PKU). Advanced brain imaging techniques alongside comprehensive neuropsychological and functional assessments will be employed. Short-term and long-term follow-up of participants will be conducted.


Description:

Standard treatment for Phenylketonuria (PKU) involves a lifelong, phenylalanine-restricted diet. Strict adherence to the diet is crucial, but often challenging. Large neutral amino acid (LNAA) supplementation is a potential alternative therapeutic approach for PKU management. The proposed mechanism involves competitive inhibition of phenylalanine (Phe) transport across the blood-brain barrier by high-dose LNAA, leading to reduced brain Phe levels. However, further investigation is needed to validate its efficacy and safety for PKU management. Two separate crossover studies will be conducted to assess the safety and efficacy of LNAA supplementation in PKU patients. Study 1: LNAA vs. No Treatment: This crossover trial investigates the effects of LNAA supplementation compared to no treatment. Participants will undergo both treatment phases in a randomized order: - Phase 1: Semi-free diet with LNAA [duration: 8 weeks] - Phase 2: Semi-free diet with no supplementation [duration: 1 week] Study 2: LNAA vs. Phe-restricted Diet: This crossover trial compares LNAA supplementation to the current standard treatment, the Phe-restricted diet. Participants will undergo both treatment phases in a randomized order: - Phase 1: Semi-free diet with LNAA [duration: 8 weeks] - Phase 2: Standard Phe-restricted diet [duration: 8 weeks] An optional open-label extension study will be offered to participants from both crossover studies. This study will assess the long-term safety and effectiveness of LNAA therapy over a period of 16 months. A healthy control group will be recruited to obtain baseline outcome measures. Subsequently, they will be administered LNAA supplementation for a period of 1 week and then reassessed. This project is expected to provide much-needed insights into the potential of LNAA in PKU management. The study also aims to gain a deeper understanding of the underlying pathophysiology of the disease. Finally, this work could lead to more personalized management strategies for PKU patients.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date December 2027
Est. primary completion date December 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 16 Years to 50 Years
Eligibility Patients = 16 years of age with Classical PKU molecularly confirmed via the finding of two pathogenic variants in the phenylalanine hydroxylase (PAH) gene and/or historical evidence of Phe concentrations =1200 µmol/L in the medical history Inclusion Criteria: - Treatment initiation within the first month of life (ideally < 10 days of age) - Intelligence quotient (> 84) based upon the baseline neuropsychological evaluation - Conventional dietary treatment up to minimum 15 years of age - Written informed consent - Willing and able to comply with the protocol and study procedures Exclusion Criteria: - Unable or unwilling to adhere to the requirements of the study - A female who is pregnant or breastfeeding or planning to get pregnant during the study period - Concomitant medication that may interfere with the PET analysis, as judged by the investigator - A serious neuropsychiatric disease that could interfere with the subject's ability to participate in the study at the discretion of the investigator - Concomitant treatment with sapropterin (BH4) supplementation or Pegvaliase-pqpz (PALYNZIQ) - Failing to submit at least one blood Phe home sample during the year before study initiation - Standard MRI contraindications

Study Design


Related Conditions & MeSH terms


Intervention

Other:
PreKUnil® LNAA Medical Food for PKU
PreKUnil® LNAA Medical Food for PKU is a commercially available active LNAA treatment product for PKU.

Locations

Country Name City State
Denmark Copenhagen University Hospital, Rigshospitalet Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Fasting plasma amino acids, dried blood spots (finger-prick method) Biomarkers such as the plasma Phe, Phe/Tyr ratio, Tyr/LNAA, Trp/LNAA ratio Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline
Other Brain perfusion measures Dynamic PET Imaging differences between groups and with intervention Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline
Other Adherence to dietary treatment 3-day diet record Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline
Other Brain Magnetic Resonance Imaging (MRI) Percent of patients with anatomic anomalies on MRI of the brain Inclusion
Other Wechsler Adult Intelligence Scale (WAIS) - IV Baseline measure of cognitive ability, 40-160, highest is best Inclusion
Primary Dynamic positron emission tomography (PET) imaging with the fluorine-18-labeled tracer [18F]-(E)-N-(3-iodoprop-2-enyl)-2ß-carbofluoroethoxy-3ß-(4'-methyl phenyl)nortropane ([18F]FE-PE2I) Change in specific binding ratio of dopamine transporter (DaT) with [18F]FE-PE2I Crossover trial 1: at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline Crossover trial 2: at 8 and 16 weeks from baseline Extension study: at 4 months and 12 to 16 months from baseline
Primary Computerized neuropsychological testing (responses over study iPad) Cambridge Neuropsychological Test Automated Assessment Battery (CANTAB) customized for study Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline
Secondary Behaviour Rating Inventory of Executive Function - Adult version (BRIEF-A) Patient-Reported Outcome Measure of executive functioning (ages 18 to 90), percentile, lowest is best Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline
Secondary Behaviour Rating Inventory of Executive Function - Second edition (BRIEF-2) Patient-Reported Outcome Measure of executive functioning (ages 11 to 18), percentile, lowest is best Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline
Secondary Adult attention deficit hyperactivity disorder (ADHD) Self-Report Scale (ASRS v1.1) Patient-Reported Outcome Measure of attention in adults, 0-23, lowest is best Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline
Secondary Adolescent ADHD Self-Report Scale Patient-Reported Outcome Measure of attention in adolescents, 0-75, lowest is best Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline
Secondary PKU-QOL Questionnaire Adolescent or Adult version Patient-Reported Outcome Measure of the impact of PKU and the PKU diet on quality of life Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline
Secondary Symptom Checklist-90-Revised (SCL-90-R) Patient-Reported Outcome Measure of psychopathological symptoms, percentile, lowest is best Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline
Secondary Behavior Assessment System for Children, Third Edition (BASC-3) Adolescent Self-Report form for measure of psychological general well-being, percentile, lowest is best Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline
Secondary Neuropsychological testing of flexibility and verbal fluency Change in flexibility and verbal fluency using the Delis-Kaplan Executive Function System (D-KEFS) customized for study Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline
Secondary Urine peripheral biomarkers of neurotransmitters 6-sulfatoxymelatonin and dopamine Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline
Secondary Incidence and severity of treatment-emergent adverse events (TEAEs) Subjects with at least one TEAE or serious TEAE Baseline to week 80
See also
  Status Clinical Trial Phase
Completed NCT06188728 - Husk Fiber Intervention on Metabolic Health of Centrally Obese School Teachers N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05081037 - Integrated Hyperglycaemia Incentivised Postnatal Surveillance Study (I-HIPS) N/A
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
Not yet recruiting NCT05461144 - AI Models for Non-invasive Glycaemic Event Detection Using ECG in Type 1 Diabetics
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A
Active, not recruiting NCT05505994 - The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin Phase 3
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Completed NCT03675360 - Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial N/A
Recruiting NCT05711758 - Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure
Recruiting NCT05112029 - Metabolic Profile and Adipokine Levels in Young Hyperandrogenemic Females
Recruiting NCT03682640 - Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes Phase 2
Completed NCT04854603 - Dairy Products With Reduced Sugar and Blood Glucose N/A
Recruiting NCT06024291 - Reducing Circulating Sphingolipid Levels to Optimise Cardiometabolic Health - The SphingoFIT Trial N/A
Recruiting NCT04904601 - Freeze-dried Kale to Reduce Metabolic Risk in Saudi Subjects N/A
Recruiting NCT04109586 - Diet and Fat Mass After Traumatic Spinal Cord Injury N/A
Recruiting NCT06009653 - Effect of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity Phase 4
Completed NCT03067012 - Nutritional Safety and Metabolic Benefits of Oncometabolic Surgery for Obese Gastric Cancer Patients N/A
Recruiting NCT03309423 - Is Venous to Arterial Conversion (v-TAC) of Blood Gas Reliable in Critical Ill Patients in the ICU? N/A